#Japan #Tokyo #Medical Devices #Alfresa Group #Nagashima Medical

Acquisition of Nagashima Medical Instruments Co., Ltd.

Overview

Alfresa Holdings Corporation, headquartered in Chiyoda, Tokyo, has announced its decision to acquire all shares of Nagashima Medical Instruments, a renowned manufacturer in the field of ENT (Ear, Nose, and Throat) medical devices. This acquisition is aimed at bolstering Alfresa’s growth strategy in the medical sector by integrating Nagashima’s specialization in high-precision medical devices. The acquisition is planned to be finalized on May 27, 2026, pending the completion of share transfer agreements.

Background and Purpose

Nagashima Medical Instruments boasts over a century of experience in producing reliable medical devices tailored for ENT and head and neck surgery. The company's dedication to innovation and quality aligns perfectly with Alfresa's long-term growth strategy, termed the "Alfresa Group Mid to Long-Term Vision."

According to this strategy, medical products, including diagnostic medicines and medical devices, represent a critical area for expansion. Alfresa aims to strengthen its nationwide network for pharmaceutical and medical product distributions as stipulated in its mid-term management plan for 2025-2027. This acquisition is a step towards leveraging Nagashima's impressive track record and technical expertise to expand Alfresa’s product lineup and enhance its competitive standing in the market.

Alfresa’s management anticipates that Nagashima's robust product development capabilities and deep industry knowledge will bolster the group’s manufacturing and developmental competencies in medical devices. This integration is not just about expanding the product range; it’s also about creating synergies with Alfresa’s pharmaceutical business to increase sales opportunities across clinics and medical facilities.

The ongoing demand from academic hospitals and smaller clinics for high-quality ENT medical devices further solidifies Nagashima's reputation in the medical field, making it an ideal candidate for this strategic acquisition. The partnership is expected to allow Alfresa to streamline operations and respond more effectively to healthcare needs.

Expectations for the Future

The financial impact of this acquisition on Alfresa's current fiscal year is anticipated to be minimal, yet the long-term implications are expected to be significantly positive, driving corporate value and enhancing overall business performance in the medical segment. Alfresa's commitment to expanding its foothold in the medical arena aligns with its vision for sustainable growth and collective strength.

The company will continue to disclose relevant information regarding this acquisition as circumstances evolve. Existing shareholders and industry stakeholders can stay informed through updates on Alfresa’s official channels.

In summary, the acquisition of Nagashima Medical Instruments Co., Ltd. symbolizes a pivotal move for Alfresa Holdings in its quest to innovate and expand within the medical device sector, positioning itself as a leader in providing advanced healthcare solutions.